Commentary on Reappraisal of European guidelines on hypertension management (part II) Commentary

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Jun 30, 2010
Keywords:
hypertension, guidelines, antihypertensive therapy, combined treatment

Main Article Content

Jacek Lewandowski
Katedra i Klinika Chorób Wewnętrznych, Nadciśnienia Tętniczego i Chorób Naczyń Warszawskiego Uniwersytetu Medycznego
Piotr Jędrusik
Katedra i Klinika Chorób Wewnętrznych, Nadciśnienia Tętniczego i Chorób Naczyń Warszawskiego Uniwersytetu Medycznego

Abstract

In 2009 The European Society of Hypertension has published a scientific statement on management of hypertension. The statement updates joint ESH and ESC guidelines published in 2007. This document takes into consideration the most important data published within the last two years that warrant some changes and additions in the treatment guidelines. Statement includes new data regarding the importance of target organ damage in total cardiovascular risk stratification and new analyses on threshold and target blood pressure values during treatment. Some commentaries are dedicated to choice of antihypertensive drugs, in particular regarding the use of beta-blockers as first-line therapy, the importance of combined therapy and the use of fixed-dose combinations in the treatment of hypertension. An approach to treatment in special populations, including the very elderly in whom convincing data showing outcome benefits of antihypertensive therapy are also discussed.

Article Details

How to Cite
Lewandowski , J., & Jędrusik , P. (2010). Commentary on Reappraisal of European guidelines on hypertension management (part II). Medycyna Faktow (J EBM), 3(2(7), 42-46. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2603
Issue
Vol 3 No 2(7) (2010)
Section
Articles

Copyright © by Medical Education. All rights reserved.

References

1. Guidelines Committee. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2007; 25: 1105-1187.
2. ADVANCE Collaborative Group: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.
3. Beckett N.S., Peters R., Fletcher A.E. et al.: Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 2008; 358: 1887-1898.
4. ONTARGET Investigators, Yusuf S., Teo K.K., Pogue J. et al.: Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008; 358: 1547-1559.
5. Jamerson K., Weber M.A., Bakris G.L. et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
6. Massie B.M., Carson P.E., McMurray J.J. et al.: IPRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N. Engl. J. Med. 2008; 359: 2456-2467.
7. Beckett N.S., Peters R., Fletcher A.E. et al.: HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 2008; 358: 1887-1898.